# AirXpanders

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/airxpanders

- Industry: Medical Devices & Equipment
- Headquarters: Palo Alto, US
- Website: www.airxpanders.com
- Total disclosed funding: $32M
- Latest round: Series E (Sep 10, 2014)
- Investors on record: 7

## About

AirXpanders, Inc. specializes in innovative medical devices for breast reconstruction, employing proprietary technology that enhances the patient experience during the expansion phase of breast implant surgery.Founded in 2005 in Palo Alto, US, AirXpanders, Inc. focuses on developing advanced solutions for breast reconstruction and has undergone strategic pivots since its inception. The company was co-founded by Hela Atmani, who has a background in medical technology. In its funding history, AirXpanders raised USD 3.4 mn in a Private Placement/Follow on round led by Vivo Capital on August 2, 2018, bringing the total amount raised to USD 3.4 mn. The company has participated in 13 investment deals to date.AirXpanders, Inc. offers a unique device designed to facilitate the expansion process for patients undergoing breast reconstruction surgeries. This device provides a more comfortable experience compared to traditional methods, streamlining the treatment journey for healthcare providers and patients alike. The company's product suite is targeted primarily at medical professionals and patients seeking less invasive surgical options.In 2018, AirXpanders, Inc. reported a revenue of USD 7.82 mn, with an EBITDA of USD -22.91 mn for the same year, reflecting the challenges faced during its growth period.AirXpanders aims to enhance its product offerings with new designs intended for improved patient outcomes, although specific release dates are yet to be announced. The company is also looking to expand into new geographic markets, targeting regions in North America and Europe by the end of 2020. The recent funding of USD 3.4 mn will be strategically utilized to support these initiatives, allowing for further development of their innovative devices and broader market outreach.

## Funding rounds

- Series E, Sep 10, 2014, $5.7M — GBS Venture Partners, Vivo Capital, Prolog Ventures, GCI Venture Partners
- Series E, Jun 18, 2013, $4.3M — GBS Venture Partners, Vivo Capital, Prolog Ventures, BioForm Medical, Inc.
- Series D, May 17, 2012, $1.1M — GBS Venture Partners, Vivo Capital, Prolog Ventures
- Series D, Jan 23, 2012, $10M — GBS Venture Partners, Western Technology Investment, Vivo Capital, Heron Capital, Prolog Ventures
- Series C, Apr 1, 2010, $5M — GBS Venture Partners
- Series A, Jun 1, 2005, $5.6M — Heron Capital, Prolog Ventures

## Investors

- Heron Capital (https://capitalatlas.ai/funds/heron-capital) — Series A, Series D
- Prolog Ventures (https://capitalatlas.ai/funds/prolog-ventures) — Series A, Series D, Series E
- GBS Venture Partners (https://capitalatlas.ai/funds/gbs-venture-partners) — Series C, Series D, Series E
- Western Technology Investment (https://capitalatlas.ai/funds/western-technology-investment) — Series D
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series D, Series E
- BioForm Medical, Inc. — Series E
- GCI Venture Partners — Series E